Two hundred years since James Parkinson's essay on the shaking palsy—Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017

Jenner, Peter

doi:10.1002/mds.27104

Cited by 8 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parkinson's disease (PD) is a chronic progressive degenerative disease affecting the central nervous system (CNS) [ 1 ]. It was first described in 1817 by James Parkinson [ 2 – 6 ]. Impaired motor function is one of the characteristics of PD.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Wearable Sensor Devices in Parkinson’s Disease: A Review of Current Status and Future Prospects

et al. 2020

Parkinson's Disease

View full text Add to dashboard Cite

Parkinson’s disease (PD) decreases the quality of life of the affected individuals. The incidence of PD is expected to increase given the growing aging population. Motor symptoms associated with PD render the patients unable to self-care and function properly. Given that several drugs have been developed to control motor symptoms, highly sensitive scales for clinical evaluation of drug efficacy are needed. Among such scales, the objective and continuous evaluation of wearable devices is increasingly utilized by clinicians and patients. Several electronic technologies have revolutionized the clinical monitoring of PD development, especially its motor symptoms. Here, we review and discuss the recent advances in the development of wearable devices for bradykinesia, tremor, gait, and myotonia. Our aim is to capture the experiences of patients and clinicians, as well as expand our understanding on the application of wearable technology. In so-doing, we lay the foundation for further research into the use of wearable technology in the management of PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of Wearable Sensor Devices in Parkinson’s Disease: A Review of Current Status and Future Prospects

et al. 2020

Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…Although L-dopa is still the most effective antiparkinsonian drug [19], the development of a treatment strategy that provides the benefits of L-dopa with reduced motor complications, including wearing-off, remains a significant clinical challenge for patients with PD [20].…”

Section: Challenges To Manage Wearing-off In Patients With Pd On L-dopamentioning

confidence: 99%

Noninvasive Options for ‘Wearing-off’ in Parkinson’s Disease: A Clinical Consensus From a Panel of Uk Parkinson’s Disease Specialists

Fackrell

Carroll

Grosset

et al. 2018

Neurodegener. Dis. Manag.

View full text Add to dashboard Cite

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.

show abstract

“…Although James Parkinson described a range of non‐motor symptoms (NMS) in his description of the “shaking palsy” 200 years ago, for many years, the impact of NMS on patients with Parkinson's disease (PD) was largely overlooked . Since the development and validation of assessment instruments such as the NMS Questionnaire (NMSQ), and the PD Non‐Motor Symptoms Scale (NMSS), assessing NMS has become more acceptable in clinical practice, and in some countries (e.g., the UK) it is considered a quality standard as a patient‐reported experience measure (UK Parkinson's Audit, 2017)…”

Section: Introductionmentioning

confidence: 99%

Pilot Study of the International Parkinson and Movement Disorder Society‐sponsored Non‐motor Rating Scale (MDS‐NMS)

Martinez‐Martín

Schrag

Weintraub

et al. 2019

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Non‐motor symptoms (NMS) are integral to Parkinson's disease (PD) and have a detrimental effect on patients and their caregivers. Clinical quantification has been aided by the development of comprehensive assessments such as the Non‐Motor Symptoms Questionnaire (NMSQuest) and Scale (NMSS). The NMSS has been widely used in clinical studies and trials; however, since its validation in 2007, our understanding of NMS has changed substantially. With the support of the International Parkinson and Movement Disorder Society (IPMDS), after a detailed peer review an initiative to develop an updated version of NMSS, the MDS‐NMS was launched in 2015. Objective This paper encapsulates the data from the pre‐validation phases carried out under the auspices of the IPMDS Non‐Motor PD Study Group. Methods Item selection and wording (formatted as a rater‐based tool) were based on the NMSS, literature review, and expert consensus. Neurologists, PD patients, and healthy controls were included in the cognitive pretesting and administration of the preliminary version of the MDS‐NMS. Primary data on acceptability and reliability were obtained. Results The pilot study, carried out in English in the United Kingdom and the United States, demonstrated that the preliminary version of the MDS‐NMS was comprehensive, understandable, and appropriate. Data quality was excellent; moderate floor effect was present in patients for most MDS‐MNS domains, with some components showing weak internal consistency. The results led to additional instrument modifications. Conclusion Qualitative and quantitative research results have led to an updated NMSS, the definitive version of the MDS‐NMS, which is currently being validated.

show abstract

Two hundred years since James Parkinson's essay on the shaking palsy—Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017

Cited by 8 publications

References 21 publications

Evaluation of Wearable Sensor Devices in Parkinson’s Disease: A Review of Current Status and Future Prospects

Evaluation of Wearable Sensor Devices in Parkinson’s Disease: A Review of Current Status and Future Prospects

Noninvasive Options for ‘Wearing-off’ in Parkinson’s Disease: A Clinical Consensus From a Panel of Uk Parkinson’s Disease Specialists

Pilot Study of the International Parkinson and Movement Disorder Society‐sponsored Non‐motor Rating Scale (MDS‐NMS)

Contact Info

Product

Resources

About